Form 4 for JANX Janux Therapeutics, Inc.
Accepted 2025-01-08 00:00:00 ET · period of report 2025-01-07 · accession 0001415889-25-001165 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-01-08 | 2025-01-07 | JANX | Campbell David Alan | Pres, CEO, Dir | S - Sale | $60.00 | -5,000 | 293.1K | -2% | -$300.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-07 | S | D | 5,000 | $60.00 | 293,054 | D | — | — | (F2) The weighted average sale price for the transaction reported was $60.0008 and the range of prices were between $60.00 and $60.02. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |